drugset

drugset / Trial / NCT02192294

Absolute Bioavailability Of Bosutinib

NCT02192294 ↗

Phase 1 Completed 14 enrolled Pfizer

CrossoverOpen-labelBasic science

Summary

This is an open-label, randomized, single-dose, one-cohort, two-sequence, two-period crossover study in healthy subjects.

Timeline

Start: 2014-08
Primary completion: 2014-10
Completion: 2014-10

Publications

Hsyu PH, Pignataro DS, Matschke K. Absolute Bioavailability of Bosutinib in Healthy Subjects From an Open-Label, Randomized, 2-Period Crossover Study. Clin Pharmacol Drug Dev. 2018 May;7(4):373-381. doi: 10.1002/cpdd.396. Epub 2017 Oct 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bosutinib	Small molecule	120 mg	Oral
Subject	Bosutinib	Small molecule	500 mg	Oral

Indications

No indication recorded.